Identification of potential leukocyte antigen-related protein (PTP-LAR) inhibitors through 3D QSAR pharmacophore-based virtual screening and molecular dynamics simulation. Issue 14 (21st September 2020)

• Record Type: Journal Article
• Authors: Du, Shan; Yang, Bing; Wang, Xin; Li, Wei-Ya; Lu, Xin-Hua; Zheng, Zhi-Hui; Ma, Ying; Wang, Run-Ling
• Is Part Of: Journal of biomolecular structure & dynamics. Volume 38:Issue 14(2020)
• Page Start: 4232
• Page End: 4245
• Publication Date: 2020-09-21
• Subjects: PTP-LAR -- 3D QSAR -- docking -- molecular dynamic simulation -- post-dynamics analyses; Biomolecules -- Periodicals; Molecular structure -- Periodicals; Molecular Biology -- Periodicals; Biomechanics -- Periodicals; 572
• DOI: 10.1080/07391102.2019.1676825
• Languages: English
• ISSNs: 0739-1102

Abstract

Abstract: Owing to its negative regulatory role in insulin signaling, protein tyrosine phosphatase of leukocyte antigen-related protein (PTP-LAR) was widely thought as a potential drug target for diabetes. Now, it was urgent to search for potential LAR inhibitors targeting diabetes. Initially, the pharmacophore models of LAR inhibitors were established with the application of the HypoGen module. The cost analysis, test set validation, as well as Fischer's test was used to verify the efficiency of pharmacophore model. Then, the best pharmacophore model (Hypo-1-LAR) was applied for the virtual screening of the ZINC database. And 30 compounds met the Lipinski's rule of five. Among them, 10 compounds with better binding affinity than the known LAR inhibitor (BDBM50296375) were discovered by docking studies. Finally, molecular dynamics simulations and post-analysis experiments (RMSD, RMSF, PCA, DCCM and RIN) were conducted to explore the effect of ligands (ZINC97018474 and Compound 1 ) on LAR and preliminary understand why ZINC97018474 had better inhibitory activity than Compound 1 (BDBM50296375). Communicated by Ramaswamy H. Sarma